MX2025007723A - Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor - Google Patents

Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor

Info

Publication number
MX2025007723A
MX2025007723A MX2025007723A MX2025007723A MX2025007723A MX 2025007723 A MX2025007723 A MX 2025007723A MX 2025007723 A MX2025007723 A MX 2025007723A MX 2025007723 A MX2025007723 A MX 2025007723A MX 2025007723 A MX2025007723 A MX 2025007723A
Authority
MX
Mexico
Prior art keywords
treatment
modified sugar
sugar groups
heat shock
shock protein
Prior art date
Application number
MX2025007723A
Other languages
English (en)
Spanish (es)
Inventor
Xin Jiang
Melean Visnick
Christopher F Bender
Gary Bolton
Bradley CAPRATHE
Chitase Lee
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of MX2025007723A publication Critical patent/MX2025007723A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
MX2025007723A 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor MX2025007723A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671047P 2018-05-14 2018-05-14
PCT/US2019/032292 WO2019222269A1 (en) 2018-05-14 2019-05-14 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Publications (1)

Publication Number Publication Date
MX2025007723A true MX2025007723A (es) 2025-08-01

Family

ID=67002352

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2025007723A MX2025007723A (es) 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor
MX2020012366A MX2020012366A (es) 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020012366A MX2020012366A (es) 2018-05-14 2019-05-14 Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor.

Country Status (18)

Country Link
US (2) US11827664B2 (cg-RX-API-DMAC7.html)
EP (1) EP3794009A1 (cg-RX-API-DMAC7.html)
JP (2) JP7508375B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210021457A (cg-RX-API-DMAC7.html)
CN (2) CN119285591A (cg-RX-API-DMAC7.html)
AU (2) AU2019271126B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020023277A2 (cg-RX-API-DMAC7.html)
CA (1) CA3100333A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002957A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020015380A2 (cg-RX-API-DMAC7.html)
EA (1) EA202092727A1 (cg-RX-API-DMAC7.html)
IL (2) IL309891B2 (cg-RX-API-DMAC7.html)
MX (2) MX2025007723A (cg-RX-API-DMAC7.html)
PE (1) PE20211917A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551941A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202011311YA (cg-RX-API-DMAC7.html)
UA (1) UA130486C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019222269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014019704B1 (pt) 2012-02-09 2022-05-31 University Of Kansas Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
MX2025007723A (es) 2018-05-14 2025-08-01 Reata Pharmaceuticals Inc Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor
JP6899975B2 (ja) 2018-05-14 2021-07-07 ギリアード サイエンシーズ, インコーポレイテッド Mcl−1阻害剤
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CA3294692A1 (en) 2019-11-26 2026-03-02 Gilead Sciences, Inc. Processes and intermediates for preparing mcl1 inhibitors
US12202782B2 (en) 2020-11-19 2025-01-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
US20230138729A1 (en) * 2021-09-13 2023-05-04 Rubedo Life Sciences, Inc. Coumarin Derivatives of Sugar Analogs and Uses Thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547145A1 (en) 1990-09-07 1993-06-23 Schering Corporation Antiviral 2(1h)-quinolinone compounds
DE19512886A1 (de) 1995-04-06 1996-10-10 Bayer Ag Substituierte Cycloalkene
FR2792320B1 (fr) 1999-04-19 2003-05-09 Hoechst Marion Roussel Inc Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
WO2002044192A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
JP4263095B2 (ja) 2001-09-21 2009-05-13 ノバルティス アクチエンゲゼルシャフト Aceおよびnepの両阻害剤としてのピラン誘導体
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
AU2005301957B2 (en) 2004-11-03 2012-02-23 Department Of Health And Human Services Novobiocin analogues as anticancer agents
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
JP5175191B2 (ja) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
EP2131656A4 (en) 2006-11-15 2011-12-07 Forest Lab Holdings Ltd phthalazine
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
EA019103B1 (ru) 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2009097578A1 (en) 2008-02-01 2009-08-06 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2010014617A1 (en) 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
JP5766617B2 (ja) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
BR112014019704B1 (pt) 2012-02-09 2022-05-31 University Of Kansas Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
US9422230B2 (en) 2013-05-09 2016-08-23 Council Of Scientific And Industrial Research Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
EP3066072B1 (en) 2013-11-07 2021-11-03 The University of Kansas Biphenylamide derivative hsp90 inhibitors
WO2015070238A2 (en) 2013-11-11 2015-05-14 The University Of Kansas Coumarin based hsp90 inhibitors with urea and ether substituents
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
CA3289739A1 (en) 2014-06-24 2025-11-29 The University Of Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
MX2025007723A (es) 2018-05-14 2025-08-01 Reata Pharmaceuticals Inc Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor

Also Published As

Publication number Publication date
EP3794009A1 (en) 2021-03-24
JP2024125338A (ja) 2024-09-18
KR20210021457A (ko) 2021-02-26
UA130486C2 (uk) 2026-03-04
AU2019271126A1 (en) 2020-12-10
WO2019222269A1 (en) 2019-11-21
SG11202011311YA (en) 2020-12-30
IL309891B1 (en) 2024-11-01
CN112513058B (zh) 2024-08-20
CA3100333A1 (en) 2019-11-21
IL309891B2 (en) 2025-03-01
IL278698A (cg-RX-API-DMAC7.html) 2021-01-31
US11827664B2 (en) 2023-11-28
IL309891A (en) 2024-03-01
CN112513058A (zh) 2021-03-16
CL2020002957A1 (es) 2021-04-16
IL278698B1 (en) 2024-02-01
PE20211917A1 (es) 2021-09-28
AU2024267017A1 (en) 2024-12-19
CN119285591A (zh) 2025-01-10
US20240182507A1 (en) 2024-06-06
CO2020015380A2 (es) 2020-12-21
US12595278B2 (en) 2026-04-07
US20210261592A1 (en) 2021-08-26
IL278698B2 (en) 2024-06-01
JP7508375B2 (ja) 2024-07-01
MX2020012366A (es) 2021-02-09
AU2019271126B2 (en) 2024-08-29
EA202092727A1 (ru) 2021-04-20
JP2021524439A (ja) 2021-09-13
BR112020023277A2 (pt) 2021-02-23
PH12020551941A1 (en) 2021-08-16

Similar Documents

Publication Publication Date Title
PH12020551941A1 (en) Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
ZA202502606B (en) Compounds and methods targeting human tau
MX2022016427A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
EP4427815A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
EA202090555A1 (ru) Фармацевтические композиции, содержащие антитела к бета-амилоиду
WO2018039475A8 (en) Use of pridopidine for treating dystonias
EP4464317A3 (en) Compounds and compositions and uses thereof
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
BR112017022568A2 (pt) compostos e seus usos como inibidores de bace1
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
JOP20240254A1 (ar) عمليات ومركب وسيط لتحضير واسع النطاق لـ 2، 4، 6-تراي فلورو-n--بنزاميد هيمي سكسينات، وتحضير 2، 4، 6-تراي فلورو-n--بنزاميد أسيتات
EP4553065A3 (en) Novel compounds for treating mitochondrial disease
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2022000712A (es) Moduladores de nlrp3.
MY207469A (en) Therapeutic compounds
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
EA201791367A1 (ru) Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы
PH12019500198A1 (en) Compounds and compositions and uses thereof
BR112021019110A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
MA42455B1 (fr) Nouveau composé hétérocyclique, procédé de préparation associé et composition pharmaceutique le comprenant
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
EA201890769A1 (ru) Производные 2,3,4,5-тетрагидропиридин-6-амина
MY199288A (en) Benzodiazepine derivative with activity on the central nervous and vascular systems
BR112022000874A2 (pt) Composições e métodos para o tratamento de síndrome de sanfilippo e outras doenças